BridgeBio Enters Collaboration with Cincinnati Children’s to Accelerate Development of Genetic Disease Therapeutics

Rare Daily Staff

BridgeBio Pharma and Cincinnati Children’s Hospital Medical Center said they are entering into a research collaboration to identify and develop genetic disease therapies.

The partnership will combine BridgeBio’s strengths in therapeutic development for diseases of high unmet need with Cincinnati Children’s world-class researchers and clinicians.

“This collaboration exemplifies Cincinnati Children’s commitment to accelerating discoveries towards commercialization through win-win academic-industry partnerships,” added Mike Pistone, director of acceleration for Cincinnati Children’s Innovation Ventures, the group managing this program.

Under the terms of the agreement, BridgeBio will have the opportunity to sponsor and collaboratively develop selected research programs. The agreement represents a flexible model that facilitates accelerated genetic disease research.

January 24, 2018
Photo: Mike Pistone, director of acceleration for Cincinnati Children’s Innovation Ventures